A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell–activating factor monoclonal antibody, for rheumatoid arthritis

INTRODUCTION: The objective of this study was to evaluate the long-term safety and efficacy of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B-cell-activating factor, in rheumatoid arthritis (RA) patients. METHODS: Patients with RA who completed one of two 24-week rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenwald, Maria, Szczepanski, Leszek, Kennedy, Alastair, Veenhuizen, Melissa, Komocsar, Wendy J, Polasek, Emery, Guerrettaz, Kelly, Berclaz, Pierre-Yves, Lee, Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177512/
https://www.ncbi.nlm.nih.gov/pubmed/25168268
http://dx.doi.org/10.1186/s13075-014-0415-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177512/
https://www.ncbi.nlm.nih.gov/pubmed/25168268
http://dx.doi.org/10.1186/s13075-014-0415-2

Ejemplares similares